3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Stomach Neoplasms
3
Breast Neoplasms
3
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Breast Neoplasms, Male
2
Vulvar Neoplasms
1
Vipoma
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Testicular Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Somatostatinoma
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pleural Effusion, Malignant
1
Parathyroid Neoplasms
1
Interventions
Radiotherapy
39
pembrolizumab
37
Carboplatin
37
Cisplatin
34
Paclitaxel
26
Pemetrexed
24
Docetaxel
18
Nivolumab
17
Magnetic Resonance Spectroscopy
17
Gemcitabine
17
Bevacizumab
17
Specimen Handling
16
Cyclophosphamide
15
osimertinib
14
Radiation
13
Irinotecan
13
Etoposide
13
Erlotinib Hydrochloride
12
durvalumab
11
Topotecan
10
Cetuximab
10
Radiosurgery
9
Immunoglobulin G
8
Fluorouracil
8
Everolimus
8
Disulfides
8
Celecoxib
8
fludarabine
7
Taxes
7
Ipilimumab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Lung Neoplasms
×
Interleukin-12
×
Clear all
NCT02960594
2018-11-19
TRT-001
Inovio Pharmaceuticals
Phase 1
Completed
93 enrolled